Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is expected to continue its strong performance, with solid quarterly results and a 2026 sales season showing signs of achieving or exceeding its 1 million new covered lives target. Additionally, the implementation of California's IVF mandate in 2026 is expected to provide a significant revenue opportunity for Progyny, potentially adding $15B in TAM for the company. With a strong track record and expanding market opportunities, Progyny may continue to outperform and achieve its goal of becoming a leading fertility benefits provider.

Bears say

Progyny is facing several challenges in the short and long term that could negatively impact the company's financial performance. These challenges include potential economic uncertainty impacting purchasing decisions and member utilization, a competitive marketplace with traditional health plan carriers and private tech-enabled health companies, and potential changes in government regulations. Furthermore, the company's current valuation at only 7x NTM EV/adjusted EBITDA is a discount compared to its peers with similar growth and margins.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.